Asia
TLC announced financial results for the first quarter ended March 31, 2019, and provided a business update.
Eisai Co., Ltd. and the UK Dementia Research Institute announced the launch of a joint post-doctoral programme to support the advancement of novel dementia research.
Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.
The sale of Xiidra to Novartis and TachoSil to Ethicon is part of Takeda’s strategy to pare down debt from its $62 billion acquisition of Shire.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
Less than one year after securing a toehold in the United States, Korea-based Enzychem Lifesciences hit a major milestone with its pipeline as it eyes completion of its Phase II CRIOM (Chemoradiation Induced Oral Mucositis) study, which could lead to eventual commercialization of a treatment for the serious cancer treatment by-product.
The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.
PRESS RELEASES